Home           |           About Us           |           Register Free           |           Events and Conferences           |           Contact Us

Graffinity is the premier partner for fragment based drug discovery and lead development of small molecule pharmaceuticals. Graffinity has built an unique approach which includes chemical microarrays, fragment screening, SPR label-free imaging of protein-ligand interactions, computational chemistry and lead discovery. The technology platform offers a new drug discovery paradigm for the rapid conversion of genomic information into novel, high quality leads and drug candidates.

Website : www.graffinity.com

maxa is dedicated to enhance the speed and quality of basic and pharmaceutical research in academia and industry, and aspires to make a significant contribution to the development of causal therapies for the treatment of severe diseases.

Website : www.amaxa.com

Coley Pharmaceutical Group is the leader in the discovery and development of a breakthrough class of immunotherapy drug candidates with broad clinical and commercial potential.

Website : www.coleypharma.com

MorphoSys is one of the world’s leading biotechnology companies focusing on fully human antibodies. With its proprietary technologies, MorphoSys is developing not only the next generation of therapeutic antibodies, but also antibodies for research and diagnostics purposes. HuCAL® (Human Combinatorial Antibody Library) is a very powerful technology for the rapid and automated production of specific antibodies.

Website : www.morphosys.com

Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies.

The route to success we have chosen is "How we deliver Value through Innovation". Sharing our customers aspirations and needs and meeting them by finding new ways to achieve greater value in everything we do is one facet of it.

Website : www.boehringer-ingelheim.com

Chiron.com is the place to find information on products and services provided by the Chiron business unit of Novartis Vaccines and Diagnostics. We recently updated the site to enhance your experience, improving functionality, accessibility and style.

Website : www.chiron.com

Biovertis is a privately-held, Austrian biotechnology company focusing on the development of novel classes of small molecule antibacterials. The antibiotics market is currently dominated by drug classes that have been in use for decades. However, an alarming rise in pathogens that are resistant to these types of drugs has created an urgent, unmet medical need in this field. With an advanced pipeline of proprietary compounds, all of which are characterized by a novel therapeutic mode of action, Biovertis addresses exactly this demand. Biovertis' team has dedicated drug development expertise to take its candidates efficiently forward through clinical trials. Oxaquin, the most advanced candidate, has entered clinical development in Q3, 2006.

Website : www.biovertis.com

Profos AG is a leading German biotech company engaged in the development of products for the capture and detection of bacteria and bacterial components (endotoxins) based on advanced, proprietary phage-ligand technology. Profos’ patented technologies utilize the highly specific and strong interaction of a variety of naturally occurring bacteriophages (bacterial viruses) with their bacterial hosts.

Website : www.profos.de

U3 Pharma AG is an emerging leader in targeted cancer drug development. The company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Prof. Axel Ullrich.

Website : www.u3pharma.com

We are dedicated to the fight against cancer. Our aim and inspiration is to help cancer patients and we aim to develop, market novel and effective cancer therapeutics

Website : www.topotarget.com

Wyeth is a global leader in pharmaceuticals, consumer health care products, and animal health care products.

Wyeth improves the lives of millions of people around the world with its outstanding products. And new, innovative medicines are on the way. With research and development (R&D) programs focused on small molecules, vaccines and biotechnology, Wyeth is exploring more than 60 new therapies for medical conditions such as diabetes, breast cancer, multiple sclerosis, HIV, Alzheimer’s disease and schizophrenia.

Website : www.wyeth.com

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines.

The company was founded in 1987 on the discovery of a hormone, amylin, produced by the same beta cells of the pancreas that make insulin. Since then, Amylin has built a strong foundation on research and development. Amylin's scientists are primarily focused on investigating the potential utility of new peptide hormone candidates. The company has amassed significant research and clinical expertise in metabolic medicine including the areas of diabetes, obesity and cardiovascular disease.

Website : www.amylin.com

Amgen strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or even save lives.

Website : www.amgen.com

MediGene's vision is the expansion of the potentials in medicine by means of utilizing biotechnology in a responsible manner. We apply state-of-the-art technologies in the development of innovative drugs for the treatment of cancer and autoimmune diseases. MediGene pursues the strategy of integrating all core areas of a modern biopharmaceuticals company from research to drug development and commercialization

Website : www.medigene.de

As a global, broad-based health care company, Abbott build upon their internal scientific expertise to bring new products to market. Their work across their broad lines of business gives them a wealth of knowledge, understanding and capabilities in a number of health areas. This expertise helps them to advance medical science, enabling people to live healthier lives.

Website : www.abbott.com